State aid to airports


A table summarizing the decisions made by the European Commission concerning financle aid granted to airports since the adoption of the 2014 Aviation Guidelines is available at this link.  


Comments

Unknown said…
Hello. Great article.
July 24, 2020 at 5:22 AM
Post a Comment

Popular posts from this blog

Geographical allocation of turnover in aviation mergers: What the European Commission recently hold

The European Merger Control Regulation (ECMR) stipulates that only concentrations with a European dimension fall within the regulatory jurisdiction of the European Commission to review. A concentration is presumed to have such a dimension when it meets the financial threshold in Article 1 of the ECMR. To this end, it is necessary to calculate the turnover generated by the merging parties within the Community or in one or more member states. However, the geographical allocation of the turnover required by Article 1 for the purpose to establish the Commission’s jurisdiction can be a tricky issue in case of mergers between undertakings with a cross-border activity such airliners. In fact, the activities of airlines span several countries as they typically operate flights and sell tickets in many national markets. Recently, the Commission has dealt with the issue at length in the Ryanair/Aer Lingus case. It identified three possible methodologies for geographical allocation of turnover: -...
Read more

Aspen: The Italian Competition Authority fines a generic manufacturer of drugs for excessive pricing

By the decision made on 29 September 2016 in Aspen [i] , the Italian Competition Authority (ICA) has imposed a fine of more than EUR 5 million on the Aspen group (Aspen), a South African manufacturer of generic drugs. Aspen violated Article 102 TFEU by imposing excessive prices for the supply of the so-called ‘Cosmos drugs’. These drugs included Leukeran, Alkeran, Purinethol and Tioguanine, which included the active principles of chlorambucil, melphalan, mercaptopurine and tioguanine, respectively. All these drugs were used to treat cancer pathologies and included in a wider package of pharmaceutical products, whose marketing rights had been purchased by Aspen from the originator GlaxoSmithKline (GSK) in 2009. Aspen had a dominant position in the relevant product markets for the commercialization of anti-cancer drugs manufactured using the active principles of alkeran, leukeran, purinethol and tioguanine. It had the only one market authorization for the sale of drugs and potential ...
Read more

The Pilkington judgment: The Court of Justice clarifies the criteria for setting fines for cartels

Introduction Article 23(2) of Regulation (EC) 1/2003 and the European Commission’s Setting Fines Guidelines [1] lay down the criteria for the determination of fines for the infringement of the EU Competition rules. Not astonishingly, one of the most often debated issues in competition litigation is whether the Commission has correctly applied those criteria, particularly in relation to cartel cases where the amounts of penalties may be hefty. In the judgment recently handed down in Pilkington [2] , a follow-on case of the Commission’s cartel decision in Car Glass [3] , the Court of Justice of the EU (CJEU) clarified which turnover of cartelists and which exchange rate to convert such turnover into euro should be used for the purpose of calculating the competition fines. The applicants, a numbers of firms belonging to the Pilkington group (thereinafter the Pilkington group), contended that the Commission, and later the General Court of the EU (GC) that upheld the Commission infring...
Read more